Patents by Inventor David A. Weber

David A. Weber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating retinopathy with extended therapeutic effect
    Patent number: 8911768
    Abstract: Methods for treating and preventing retinopathic conditions by administering an anti-VEGF compound to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: December 16, 2014
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, David A. Weber
  • METHODS FOR TREATING RETINOPATHY WITH EXTENDED THERAPEUTIC EFFECT
    Publication number: 20140328835
    Abstract: Methods for treating and preventing retinopathic conditions by administering an anti-VEGF compound to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.
    Type: Application
    Filed: June 17, 2014
    Publication date: November 6, 2014
    Inventors: Scott M. Whitcup, David A. Weber
  • ALPHA-1-ANTITRYPSIN COMPOSITIONS
    Publication number: 20140323405
    Abstract: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.
    Type: Application
    Filed: March 24, 2014
    Publication date: October 30, 2014
    Applicant: CSL Behring L.L.C.
    Inventors: Scott M. Kee, Paul I. Cook, James R. Smith, Robert Kling, Scott A. Fowler, David Weber
  • Methods for treating retinopathy with extended therapeutic effect
    Patent number: 8802129
    Abstract: Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: August 12, 2014
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, David A. Weber
  • Ocular implant made by a double extrusion process
    Patent number: 8778381
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: July 15, 2014
    Assignee: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • RAPAMYCIN FORMULATIONS AND METHODS OF THEIR USE
    Publication number: 20140194461
    Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
    Type: Application
    Filed: January 9, 2014
    Publication date: July 10, 2014
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Sreenivasu MUDUMBA, Philippe JM DOR, Thierry NIVAGGIOLI, David A. WEBER, Sidiq FAROOQ
  • Notification method for a dynamic document system
    Patent number: 8745075
    Abstract: A dynamic document template contains a set of queries. Each query may include a query scope. The query scope may refer to a content of a source document that is maintained in a document collection. A content rule is applied to monitor the template for a change. A notification event is triggered when a change to the document collection results in an invalid query scope in the template. A notification event may also be triggered when a change to the document collection results in valid query but the template needs to be refreshed. An additional notification event may be triggered if the template is modified so that the resulting template is either invalid or needs to be refreshed with different content from the collection.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: June 3, 2014
    Assignee: Xerox Corporation
    Inventors: Dale Ellen Gaucas, Scott David Weber
  • Alpha-1-antitrypsin compositions and methods of use
    Patent number: 8722624
    Abstract: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: May 13, 2014
    Assignee: CSL Behring LLC
    Inventors: Scott M Kee, Paul I Cook, James R Smith, Robert Kling, Scott A Fowler, David Weber
  • Formulations for treating ocular diseases and conditions
    Patent number: 8663639
    Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: March 4, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Philippe J. M. Dor, Sreenivasu Mudumba, Thierry Nivaggioli, David A. Weber, Sidiq Farooq, Sudeep Takhar
  • DISPOSABLE ELECTROTHERMAL CAUTERIZATION AND LIGATION TOOL
    Publication number: 20140046325
    Abstract: A disposable device for tissue cauterization, including a generally electrically insulating housing assembly and a generally electrically conducting elongated assembly. The housing assembly includes a barrel having a cylindrical aperture formed therethrough, a grip extending from the barrel, a trigger slidingly connected to the barrel, a spring connected to the trigger, and an end plug positioned adjacent the proximal end of the barrel. The elongated assembly includes a hollow elongated outer cylinder disposed within the barrel and extending from the distal end, a generally hollow elongated inner cylinder slidably disposed within the elongated outer cylinder and extending to snugly engage the end plug, and bipolar forceps operationally connected to the distal end of the elongated inner cylinder and defining a leaf spring.
    Type: Application
    Filed: August 8, 2012
    Publication date: February 13, 2014
    Inventors: David Weber, Thomas P. Clement
  • Ceramic matrix composite shroud attachment system
    Patent number: 8647055
    Abstract: Shroud assembly for use in a turbine, having an outer shroud having a side proximate to flow of operative fluid of the turbine, the side having a boss and an outer shroud aperture extending through the boss. An inner shroud is located between the side of the outer shroud proximate to the flow of operative fluid and the operative fluid flow of the turbine, the inner shroud having an inner shroud aperture which is dimensioned to fit over the boss.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: February 11, 2014
    Assignee: General Electric Company
    Inventors: Gregory Thomas Foster, Robert Coign, Kevin McGovern, David Weber
  • System For Generation Of Useful Electrical Power From Isotopic Emissions
    Publication number: 20140035435
    Abstract: Particles emitted by radio-isotopic by-products of nuclear fission are used as a power source at the cathode of a magnetron system. Particles include high energy electrons having a large associated EMF. In the system a radial electrical vector E, between the cathode and anode, interacts with an axial magnetic vector B vector to produce an E×B force that rotates the particles about the system axis. These emissions are within a set range of velocities. The angular velocity and geometry of a rotating field, known as a space charge wheel (SCW), may be modulated by an external RF inputs to cavities of an anode block and the use of concentric biasing grids between the cathode and anode block. The SCW induces LC values into cavities of the anode, exciting them and producing electrons resonance which may be used to generate power.
    Type: Application
    Filed: August 7, 2013
    Publication date: February 6, 2014
    Inventor: David Weber
  • Rapamycin formulations and methods of their use
    Patent number: 8637070
    Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: January 28, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
  • Methods for treating retinopathy with extended therapeutic effect
    Publication number: 20130302324
    Abstract: Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.
    Type: Application
    Filed: July 19, 2013
    Publication date: November 14, 2013
    Inventors: Scott M. Whitcup, David A. Weber
  • OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCES
    Publication number: 20130295157
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Application
    Filed: June 20, 2013
    Publication date: November 7, 2013
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS
    Publication number: 20130231318
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 5, 2013
    Applicant: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Ocular implant made by a double extrusion process
    Patent number: 8506987
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: August 13, 2013
    Assignee: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Formulations and methods for vascular permeability-related diseases or conditions
    Patent number: 8486960
    Abstract: Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: July 16, 2013
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: David M. Kleinman, Thierry Nivaggioli, Mary E. Gerritsen, David A. Weber
  • Error detection and correction in data and control words
    Patent number: 8413006
    Abstract: A method and system are provided to detect and correct errors in the Interlaken block code overhead bits. Specifically, a method is provided for determining the original transmitted information with a very high probability of correct interpretation. These approaches can also characterized by their minimal complexity. Further, such a method can operate on the received information in a manner that does not require consideration of special cases. Also, the method does not require the source to send any extra information or alter its current behavior in any way. Thus, the approaches described herein are compatible with all existing Interlaken sources and can provide immediate benefits.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: April 2, 2013
    Assignees: PMC-Sierra, Inc., Open-Silicon, Inc.
    Inventors: Winston Ki-Cheong Mok, Steven Scott Gorshe, Matthew David Weber
  • Liquid formulations for treatment of diseases or conditions
    Patent number: 8367097
    Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: February 5, 2013
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq